BioSpace News Archive

Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced that the Company’s management team will present and participate in one-on-one meetings at the following investor conferences.

Enovis™ Corporation announced it will showcase the latest technologies from its Surgical business, including an updated ARVIS® Augmented Reality System, EMPOWR™ blade stem, and EMPOWR 3D Knee® at the American Association of Hip and Knee Surgeons annual meeting in Grapevine, Texas, November 2-5, 2023.

Apogee Therapeutics, Inc. today announced that management will present at the following upcoming investor conferences.

Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2023.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage genetic medicines company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced alignment with the U.S. Food and Drug Administration (FDA) on a plan to lift the clinical hold on the Phase 1/2 INGLAXA clinical trial in the United States for 4D-310 for Fabry disease cardiomyopathy.

Cullinan Oncology, Inc. today announced its participation in the following upcoming investor conferences.

Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).

BioVie Inc. today announced that the Company’s management will host a conference call and webcast on Wednesday, November 1 2023 at 8:00 AM Eastern Time.

Akeso (9926.HK) announced that the results of a phase Ib clinical trial for PD-1/VEGF bispecific antibody ( ivonecimab AK112/SMT112 ) as first- or second-line therapy for advanced or metastatic immunotherapy naïve non-small-cell lung cancer (NSCLC) were published in the Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC).

Triumvira Immunologics today announced that it will participate with one oral presentation and four posters at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, California, from November 1-5.